<p>The clinical datasets used for the calibration and validation of the integrated models with pamidronate and denosumab.</p
The effect of adding clinical parameters to radiomics data on model performance for the combined val...
Model details including chemotherapeutic agents, route of administration, median cumulative dose, an...
<p>Model calculations compared to data, with combination therapy prediction using parameters derived...
<p>The calibrated parameter values of the integrated models with pamidronate and denosumab.</p
<p>(a) The calibration of the integrated model with denosumab according to the NTX levels. (b) The v...
<p>Evaluations of the calibration and validation of pharmacokinetic models of pamidronate and denosu...
<p>The calibrated parameter values of the pharmacokinetic models of pamidronate and denosumab.</p
<p>(a) The calibration of the pharmacokinetic model of denosumab. (b) The validation of the pharmaco...
<p>Note 1: The r<sup>2</sup> is calculated before 30 days after pamidronate treatment.</p><p>Note 2:...
<p>(a) Denosumab. (b) Pamidronate. m<sub>1</sub>: muscle; m<sub>2</sub>: blood; m<sub>3</sub>: bone....
Datasets (systems and benchmarks) used in the selected studies to train RNN models.</p
List of tumor (T) and non-tumor (N) samples and datasets used for model training and validation.</p
<p>Clinical data and neutralization screening results for the patient groups.</p
<p>Clinical, physiological and blood parameters measured in patients included in the prediction set....
<p>(a) The active osteoclasts after multi–dose administration every 30 days. (b) The MM-cell density...
The effect of adding clinical parameters to radiomics data on model performance for the combined val...
Model details including chemotherapeutic agents, route of administration, median cumulative dose, an...
<p>Model calculations compared to data, with combination therapy prediction using parameters derived...
<p>The calibrated parameter values of the integrated models with pamidronate and denosumab.</p
<p>(a) The calibration of the integrated model with denosumab according to the NTX levels. (b) The v...
<p>Evaluations of the calibration and validation of pharmacokinetic models of pamidronate and denosu...
<p>The calibrated parameter values of the pharmacokinetic models of pamidronate and denosumab.</p
<p>(a) The calibration of the pharmacokinetic model of denosumab. (b) The validation of the pharmaco...
<p>Note 1: The r<sup>2</sup> is calculated before 30 days after pamidronate treatment.</p><p>Note 2:...
<p>(a) Denosumab. (b) Pamidronate. m<sub>1</sub>: muscle; m<sub>2</sub>: blood; m<sub>3</sub>: bone....
Datasets (systems and benchmarks) used in the selected studies to train RNN models.</p
List of tumor (T) and non-tumor (N) samples and datasets used for model training and validation.</p
<p>Clinical data and neutralization screening results for the patient groups.</p
<p>Clinical, physiological and blood parameters measured in patients included in the prediction set....
<p>(a) The active osteoclasts after multi–dose administration every 30 days. (b) The MM-cell density...
The effect of adding clinical parameters to radiomics data on model performance for the combined val...
Model details including chemotherapeutic agents, route of administration, median cumulative dose, an...
<p>Model calculations compared to data, with combination therapy prediction using parameters derived...
DOI
Add to ORKG